Cargando…
SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY
Previous results of the ongoing single-arm, phase 2 LITESPARK-004 (NCT03401788) study showed clinically meaningful antitumor activity with the HIF-2α inhibitor belzutifan for von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), CNS hemangioblastomas, and other neoplasms. Adults wit...
Autores principales: | Narayan, Vivek, Iliopoulos, Othon, Iversen, Ane B, Maughan, Benjamin L, Beckermann, Kathryn E, Oudard, Stephane, Else, Tobias, Maranchie, Jodi K, Fu, Wei, Perini, Rodolfo F, Liu, Yanfang, Linehan, W Marston, Srinivasan, Ramaprasad, Jonasch, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402338/ http://dx.doi.org/10.1093/noajnl/vdad070.122 |
Ejemplares similares
-
First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma
por: Dhawan, Andrew, et al.
Publicado: (2022) -
Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL
por: Arevalo, Aileen, et al.
Publicado: (2022) -
Resection of von Hippel Lindau Related Brainstem Hemangioblastoma
por: Maggio, Dominic, et al.
Publicado: (2019) -
Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau
por: Gomella, Patrick T., et al.
Publicado: (2019) -
Von Hippel-Lindau Syndrome: Diagnosis and Management of Hemangioblastoma and Pheochromocytoma
por: Vaganovs, P., et al.
Publicado: (2013)